Abstract
Current Medicinal Chemistry - Central Nervous System Agents
Title: Subject Index to Volume 3
Volume: 4 Issue: 1
Author(s): Bentham Science Publishers
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Bentham Science Publishers , Subject Index to Volume 3, Current Medicinal Chemistry - Central Nervous System Agents 2004; 4 (1) . https://dx.doi.org/10.2174/1568015043477612
DOI https://dx.doi.org/10.2174/1568015043477612 |
Print ISSN 1568-0150 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6158 |
10
Related Articles
-
The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety An Overview of Parkinsons Disease and the Cannabinoid System and Possible Benefits of Cannabinoid-Based Treatments
Current Medicinal Chemistry Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Antipsychotic Polypharmacy
Current Pharmaceutical Design Randomized Placebo-Controlled Trials of Omega-3 Polyunsaturated Fatty Acids in Psychiatric Disorders: A Review of the Current Literature
Current Drug Discovery Technologies The Role of Binding Kinetics in GPCR Drug Discovery
Current Topics in Medicinal Chemistry Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Partial Dopamine Agonists and the Treatment of Psychosis
Current Neuropharmacology Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Current Drug Targets GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Pharmacologic Treatments in “Prodromal Psychosis:” Making Clinical Decisions in the Absence of a Consensus
Adolescent Psychiatry Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole
Current Pharmacogenomics Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism